W
WAVEMAN · COMPANY
G · Genpact Ltd
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

G

Genpact LTD
PHARMA & BIOTECH · SERVICES-MANAGEMENT CONSULTING SERVICES · CIK 0001398659
FORM 144 · 5☆ WATCH
INSIDER NET · 180D
-$1.9M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
250
13F, latest reported quarter
REVENUE GROWTH
+6.6%
XBRL, annual
NET MARGIN
10.9%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$1.9M over 180 days
-$1.9M over 90 days
below 67% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
250 funds added or opened last quarter
more than 91% of Pharma & Biotech
REVENUE
+6.6% year over year
more than 56% of Pharma & Biotech
MARGIN
10.9% net margin
more than 82% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
6.6% of shares outstanding short · 5.2 days to cover · settled 2026-07-31
more than 63% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$1.9M across 3 people in 180 days.
250 funds added or opened positions in the latest 13F quarter, of 481 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -15.3%
-15.3%12M
-38%-22%-7%+8%2025-092025-102025-122026-032026-052026-072026-09 2025-09-12 · Mehta Piyush sold $2.1M2025-11-13 · White Heather sold $2.1M2025-09-11 · Kalra Balkrishan sold $1.7M2025-11-11 · Dewan Sameer sold $1.2M2025-09-12 · Mehta Piyush sold $1.1M2026-01-13 · Vashisht Riju sold $747.1K2026-01-13 · Dewan Sameer sold $703.9K2025-09-11 · Kalra Balkrishan sold $650.9K2025-11-14 · Weiner Michael Hal sold $599.3K2026-08-11 · Nanduru Anil sold $585.6K2026-08-14 · Dewan Sameer sold $454.1K2026-08-12 · Nanduru Anil sold $402.0K2026-08-19 · Nanduru Anil sold $229.3K2026-08-13 · Weiner Michael Hal sold $200.8K2025-11-12 · White Heather sold $199.0K2025-11-12 · Franklin Tamara sold $125.5K2025-09-03 · Klunk Donald J sold $120.7K2026-03-04 · Kalra Balkrishan sold $114.2K2026-08-14 · Dewan Sameer sold $56.4K2025-11-11 · White Heather sold $45.7K2026-08-19 · ANIL NANDURU filed to sell $229.2K2026-08-14 · SAMEER DEWAN filed to sell $510.6K2026-08-13 · MICHAEL H WEINER filed to sell $200.8K2026-08-12 · ANIL NANDURU filed to sell $402.0K2026-08-11 · ANIL NANDURU filed to sell $585.6K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $1.9M sold by insiders over 180 days, 250 funds added last quarter, $1.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Genpact LTD insiders sold a net $1.9M of stock across 131 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Nanduru Anil
Senior Vice President
SELL
2026-08-19
6,191.0
$229.3K
Dewan Sameer
Senior Vice President
SELL
2026-08-14
1,654.0
$56.4K
Dewan Sameer
Senior Vice President
SELL
2026-08-14
13,318.0
$454.1K
Weiner Michael Hal
Chief Financial Officer
SELL
2026-08-13
5,900.0
$200.8K
Nanduru Anil
Senior Vice President
SELL
2026-08-12
11,852.0
$402.0K
131 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 126 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
15,844,486.0 sh
$435.7M
Nalanda India Equity Fund Ltd
13,702,500.0 sh
$376.8M
FMR LLC
10,405,025.0 sh
$286.1M
VANGUARD PORTFOLIO MANAGEMENT LLC
10,304,410.0 sh
$283.4M
AQR CAPITAL MANAGEMENT LLC
8,601,538.0 sh
$232.8M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
ANIL NANDURU
FILED 2026-08-19
$229.2K
SAMEER DEWAN
FILED 2026-08-14
$510.6K
MICHAEL H WEINER
FILED 2026-08-13
$200.8K
ANIL NANDURU
FILED 2026-08-12
$402.0K
ANIL NANDURU
FILED 2026-08-11
$585.6K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Vulcan Value Partners Small Cap Fund
$3.4M POSITION · AS OF 2026-04-30
3.8%
Tandem Fund
$718.9K POSITION · AS OF 2026-03-31
3.5%
Monarch Dividend Plus Index ETF
$2.0M POSITION · AS OF 2026-02-28
3.4%
PL Growth and Income ETF
$1.7M POSITION · AS OF 2026-03-31
2.9%
Formidable ETF
$549.1K POSITION · AS OF 2026-03-31
2.7%
Counterpoint Quantitative Equity ETF
$4.2M POSITION · AS OF 2026-03-31
2.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · N.V. Tyagarajan
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2023
$10.0M
-$3.8M
$3.1M
-14%
+70%
2022
$4.2M
$694.3K
$3.0M
+13%
+37%
2021
$6.6M
$27.4M
$4.3M
+28%
+108%
2020
$5.3M
$3.4M
$2.5M
-1%
+37%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$5.1B$4.8B$4.5B$4.4B
GROSS PROFIT$1.8B$1.7B$1.6B$1.5B
OPERATING INCOME$750.2M$702.1M$630.9M$502.2M
NET INCOME$552.5M$513.7M$631.3M$353.4M
EPS (DILUTED)3.132.853.411.88
OPERATING CASH FLOW$812.9M$615.4M$490.8M$443.7M
CASH$853.8M$648.2M$583.7M$646.8M
LONG-TERM DEBT$1.2B$1.2B$824.7M$1.2B
BUYBACKS—$252.7M$225.5M$214.1M
DIVIDENDS PAID$117.7M$108.5M$100.0M$91.8M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →